Loading
A phase 1/2 trial of Purinostat in advanced solid tumours, run by Chengdu Zenitar Biomedical Technology Co., Ltd, now recruiting.
A Clinical Study of Purinostat Mesylate for Injection in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06431243 by Chengdu Zenitar Biomedical Technology Co., Ltd, with 132 participants planned, started 2024-05-08 and due to reach its primary completion in 2026-05-01. Interventions recorded: A0/B0 group Purinostat Mesylate 11.2mg/m2, A0/B0 group Purinostat Mesylate 15mg/m2, A group Purinostat Mesylate 6mg/m2, A group Purinostat Mesylate 8.4mg/m2, A group Purinostat Mesylate 11.2mg/m2 and A group Purinostat Mesylate 15 mg/m2.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Purinostat, Chengdu Zenitar Biomedical Technology and the tag pipeline.
Shares Purinostat, Chengdu Zenitar Biomedical Technology and the tag pipeline.
Shares Chengdu Zenitar Biomedical Technology and the tag pipeline.
Shares Chengdu Zenitar Biomedical Technology and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/